What is Stivarga (regorafenib)?
Stivarga is the brand name for regorafenib, an oral cancer medicine used to treat certain advanced cancers, typically after other treatments have failed or when the disease has progressed. [1]
What cancers is Stivarga used for?
The specific indications for Stivarga depend on the country and the latest label. Regorafenib has been approved for multiple tumor types, including metastatic colorectal cancer and gastrointestinal stromal tumor (GIST), among other settings. [1]
How does Stivarga work?
Stivarga (regorafenib) is a multikinase inhibitor. It targets multiple signaling pathways involved in tumor growth and angiogenesis (blood vessel formation), which is part of why it can help slow or stop cancer progression in eligible patients. [1]
How is Stivarga taken, and what should patients expect?
Stivarga is taken by mouth on a dosing schedule defined by the prescriber and product labeling. Dosing schedules often require careful monitoring for side effects, because regorafenib can cause significant treatment-related toxicities. [1]
What side effects are patients asking about most?
Common side effects associated with regorafenib/Stivarga can include fatigue, high blood pressure, hand-foot skin reaction (palmar-plantar erythrodysesthesia), and liver enzyme elevations. Clinicians monitor patients closely and may adjust dosing to manage toxicity. [1]
What monitoring is needed while on Stivarga?
Because regorafenib can affect the liver, blood pressure, and skin reactions, patients typically need periodic checks such as liver function tests and monitoring for hypertension and hand-foot symptoms, along with assessments for other adverse effects described in the prescribing information. [1]
Are there newer alternatives or competitors?
For many indications, treatment choices after progression may include other approved systemic therapies, depending on tumor type, prior lines of therapy, and patient-specific factors. If you tell me the cancer type and stage you’re asking about, I can narrow the comparison to the most relevant alternatives.
What about patents and generic/biosimilar availability?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Stivarga (regorafenib) and can help identify whether generic versions are likely to appear based on patent status. Check the Stivarga entry on DrugPatentWatch here: [1]
---
Sources
[1] DrugPatentWatch – Stivarga (regorafenib)